302 related articles for article (PubMed ID: 35035534)
41. Concurrent development of high-stage cutaneous squamous cell carcinoma during complete response of metastatic cutaneous squamous cell carcinoma to programmed cell death protein 1 blockade with cemiplimab.
Siegel JD; Bhatia A; Ko CJ; Christensen SR
JAAD Case Rep; 2021 Dec; 18():23-25. PubMed ID: 34778502
[No Abstract] [Full Text] [Related]
42. Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis.
Rischin D; Khushalani NI; Schmults CD; Guminski A; Chang ALS; Lewis KD; Lim AM; Hernandez-Aya L; Hughes BGM; Schadendorf D; Hauschild A; Thai AA; Stankevich E; Booth J; Yoo SY; Li S; Chen Z; Okoye E; Chen CI; Mastey V; Sasane M; Lowy I; Fury MG; Migden MR
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34413166
[TBL] [Abstract][Full Text] [Related]
43. Immunotherapy in advanced cutaneous squamous cell carcinoma: Sydney west cancer network experience.
Hasmat S; Howle JR; Carlino MS; Sundaresan P; Veness MJ
ANZ J Surg; 2023 Jan; 93(1-2):235-241. PubMed ID: 36567642
[TBL] [Abstract][Full Text] [Related]
44. New and emerging drugs for the treatment of advanced cutaneous squamous cell carcinoma.
Bonini F; de Sousa LG; Ferrarotto R
Expert Opin Emerg Drugs; 2023 Dec; 28(2):97-106. PubMed ID: 37144289
[TBL] [Abstract][Full Text] [Related]
45. Update on Management Recommendations for Advanced Cutaneous Squamous Cell Carcinoma.
García-Foncillas J; Tejera-Vaquerizo A; Sanmartín O; Rojo F; Mestre J; Martín S; Azinovic I; Mesía R
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158897
[TBL] [Abstract][Full Text] [Related]
46. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.
Migden MR; Khushalani NI; Chang ALS; Lewis KD; Schmults CD; Hernandez-Aya L; Meier F; Schadendorf D; Guminski A; Hauschild A; Wong DJ; Daniels GA; Berking C; Jankovic V; Stankevich E; Booth J; Li S; Weinreich DM; Yancopoulos GD; Lowy I; Fury MG; Rischin D
Lancet Oncol; 2020 Feb; 21(2):294-305. PubMed ID: 31952975
[TBL] [Abstract][Full Text] [Related]
47. Multidisciplinary management of locally advanced and metastatic cutaneous squamous cell carcinoma.
Claveau J; Archambault J; Ernst DS; Giacomantonio C; Limacher JJ; Murray C; Parent F; Zloty D
Curr Oncol; 2020 Aug; 27(4):e399-e407. PubMed ID: 32905333
[TBL] [Abstract][Full Text] [Related]
48. Infrequent liver injury from cemiplimab in patients with advanced cutaneous squamous cell carcinoma.
Swanson L; Kassab I; Tsung I; Worden FP; Fontana RJ
Immunotherapy; 2022 Apr; 14(6):409-418. PubMed ID: 35232282
[TBL] [Abstract][Full Text] [Related]
49. Systemic therapy for advanced cutaneous squamous cell carcinoma.
Fitzgerald K; Tsai KK
Semin Cutan Med Surg; 2019 Mar; 38(1):E67-E74. PubMed ID: 31051028
[TBL] [Abstract][Full Text] [Related]
50. The Immunomodulatory Potential of Concurrent High-Dose Radiotherapy and Immune Checkpoint Inhibitor Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma: Initial Results.
Lo Greco MC; Marano G; Milazzotto R; Liardo RLE; Finocchiaro I; La Rocca M; Basile A; Foti PV; Palmucci S; David E; Pergolizzi S; Spatola C
J Pers Med; 2024 May; 14(6):. PubMed ID: 38929802
[TBL] [Abstract][Full Text] [Related]
51. Checkpoint immunotherapy of cutaneous squamous cell carcinoma in patients suffering from chronic lymphocytic leukaemia: divergent outcomes in two men treated with PD-1 inhibitors.
Jansen P; Lodde GC; Wetter A; Welt A; Stuschke M; Dührsen U; Stoffels I; Klode J; Livingstone E; Zimmer L; Roesch A; Hadaschik E; Griewank KG; Schadendorf D; Ugurel S
J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1():41-44. PubMed ID: 34855243
[TBL] [Abstract][Full Text] [Related]
52. Treatment approaches of advanced cutaneous squamous cell carcinoma.
Peris K; Piccerillo A; Del Regno L; Di Stefani A
J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1():19-22. PubMed ID: 34855254
[TBL] [Abstract][Full Text] [Related]
53. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline.
Stratigos A; Garbe C; Lebbe C; Malvehy J; del Marmol V; Pehamberger H; Peris K; Becker JC; Zalaudek I; Saiag P; Middleton MR; Bastholt L; Testori A; Grob JJ; ; ;
Eur J Cancer; 2015 Sep; 51(14):1989-2007. PubMed ID: 26219687
[TBL] [Abstract][Full Text] [Related]
54. PD-1 Blockade With Concurrent Radiotherapy for Locally Advanced Inoperable Cutaneous Squamous Cell Carcinoma.
Joseph K; Walker J; Raziee H; Faruqi S; Smylie M
J Cutan Med Surg; 2022; 26(3):243-248. PubMed ID: 34866423
[TBL] [Abstract][Full Text] [Related]
55. Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.
Konidaris G; Paul E; Kuznik A; Keeping S; Chen CI; Sasane M; Xu Y; Atsou K; Ayers D; Ruiz ES; Khushalani NI; Cope S
Value Health; 2021 Mar; 24(3):377-387. PubMed ID: 33641772
[TBL] [Abstract][Full Text] [Related]
56. Cemiplimab-Induced Hyperosmolar Hyperglycemic State With Concurrent Diabetic Ketoacidosis in a Patient Receiving Treatment for Cutaneous Squamous Cell Carcinoma.
Pyronneau A; Noronha K; Zucker A; Kennett R; Desai P
Cureus; 2024 May; 16(5):e60565. PubMed ID: 38764707
[TBL] [Abstract][Full Text] [Related]
57. Medical treatment of advanced cutaneous squamous-cell carcinoma.
Gellrich FF; Hüning S; Beissert S; Eigentler T; Stockfleth E; Gutzmer R; Meier F
J Eur Acad Dermatol Venereol; 2019 Dec; 33 Suppl 8():38-43. PubMed ID: 31833610
[TBL] [Abstract][Full Text] [Related]
58. Immunotherapy and Systemic Treatment of Cutaneous Squamous Cell Carcinoma.
Aboul-Fettouh N; Morse D; Patel J; Migden MR
Dermatol Pract Concept; 2021 Nov; 11(Suppl 2):e2021169S. PubMed ID: 34877077
[TBL] [Abstract][Full Text] [Related]
59. Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma.
Lavaud J; Blom A; Longvert C; Fort M; Funck-Brentano E; Saiag P
Eur J Dermatol; 2019 Dec; 29(6):636-640. PubMed ID: 31903954
[TBL] [Abstract][Full Text] [Related]
60. Safe Administration of Cemiplimab to a Kidney Transplant Patient with Locally Advanced Squamous Cell Carcinoma of the Scalp.
Paoluzzi L; Ow TJ
Curr Oncol; 2021 Jan; 28(1):574-580. PubMed ID: 33477979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]